Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Oncolytic Virotherapy* ; Neoplasms* ; Herpesvirus 1, Human*/genetics ; Oncolytic Viruses*/genetics; Humans ; Tropism ; DNA Viruses

Oncolytic viruses (OVs) have emerged as one of the most promising cancer immunotherapy agents that selectively target and kill cancer cells while sparing normal cells. OVs are from diverse families of viruses and can possess either a DNA or an RNA genome. These viruses also have either a natural or engineered tropism for cancer cells. Oncolytic DNA viruses have the additional advantage of a stable genome and multiple-transgene insertion capability without compromising infection or replication. Herpes simplex virus 1 (HSV-1), a member of the oncolytic DNA viruses, has been approved for the treatment of cancers. This success with HSV-1 was achievable by introducing multiple genetic modifications within the virus to enhance cancer selectivity and reduce the toxicity to healthy cells. Here, we review the natural characteristics of and genetically engineered changes in selected DNA viruses that enhance the tumor tropism of these oncolytic viruses.

Cancers (Basel). 2018 Jul 10;10(7):. (PMID: 29996551)
Virology. 1988 May;164(1):182-92. (PMID: 3363864)
Front Microbiol. 2021 Oct 25;12:757238. (PMID: 34759908)
J Virol. 2011 Apr;85(7):3557-69. (PMID: 21270149)
Nat Biotechnol. 1998 May;16(5):444-8. (PMID: 9592392)
J Virol. 2019 Sep 12;93(19):. (PMID: 31292245)
Oncotarget. 2018 Nov 13;9(89):35891-35906. (PMID: 30542506)
Oncogene. 2008 Jul 10;27(30):4249-54. (PMID: 18345032)
J Virol. 2006 Jun;80(11):5531-9. (PMID: 16699034)
Cancer Res. 2001 Dec 15;61(24):8751-7. (PMID: 11751395)
Cancer. 2002 Sep 1;95(5):1171-81. (PMID: 12209705)
PLoS Pathog. 2005 Sep;1(1):e7. (PMID: 16201019)
Gene Ther. 2003 Feb;10(4):292-303. (PMID: 12595888)
Vaccine. 2013 Sep 6;31(39):4252-8. (PMID: 23726825)
Int J Cell Biol. 2013;2013:973584. (PMID: 23935627)
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401. (PMID: 11353831)
Cells. 2021 Jun 18;10(6):. (PMID: 34207386)
Nat Struct Mol Biol. 2010 Jul;17(7):882-8. (PMID: 20601960)
World J Gastroenterol. 2011 Oct 14;17(38):4289-97. (PMID: 22090785)
Viruses. 2018 Jun 30;10(7):. (PMID: 29966356)
J Immunother Cancer. 2019 Jan 9;7(1):6. (PMID: 30626434)
Nat Med. 2000 Aug;6(8):879-85. (PMID: 10932224)
Cancer Cell. 2015 Aug 10;28(2):210-24. (PMID: 26212250)
J Gen Virol. 2002 Aug;83(Pt 8):1965-1976. (PMID: 12124460)
Mol Cancer Ther. 2018 Feb;17(2):575-587. (PMID: 29367266)
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92. (PMID: 14734481)
Cancers (Basel). 2020 Feb 18;12(2):. (PMID: 32085583)
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9039-44. (PMID: 19458262)
Anticancer Res. 2015 Oct;35(10):5201-10. (PMID: 26408678)
PLoS Pathog. 2013 Jan;9(1):e1003155. (PMID: 23382683)
Hum Vaccin Immunother. 2021 Jun 3;17(6):1578-1585. (PMID: 33606578)
J Virol. 2012 Feb;86(4):2323-36. (PMID: 22171261)
J Neurosci. 1996 Sep 15;16(18):5644-53. (PMID: 8795620)
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7544-9. (PMID: 9636186)
J Virol. 2013 Aug;87(16):9301-12. (PMID: 23785200)
Cells. 2021 Apr 23;10(5):. (PMID: 33922406)
Virology. 2007 Nov 10;368(1):32-40. (PMID: 17632198)
Surgery. 2018 Feb;163(2):336-342. (PMID: 29174433)
Microbiol Mol Biol Rev. 1999 Sep;63(3):725-34. (PMID: 10477314)
Mol Ther Oncolytics. 2015;2:. (PMID: 26462293)
J Virol. 2008 Oct;82(20):10153-61. (PMID: 18684832)
J Transl Med. 2018 Apr 26;16(1):110. (PMID: 29699566)
Cancer Res. 2008 Apr 1;68(7):2071-5. (PMID: 18381410)
J Gen Virol. 2013 Nov;94(Pt 11):2367-2392. (PMID: 23999164)
Mol Ther Methods Clin Dev. 2020 Mar 30;17:871-893. (PMID: 32373649)
Mol Ther Oncolytics. 2020 Oct 10;19:278-282. (PMID: 33251335)
Virus Genes. 2017 Feb;53(1):52-62. (PMID: 27738905)
Immunology. 2015 May;145(1):34-49. (PMID: 25382035)
Mol Ther Oncolytics. 2021 May 19;22:85-97. (PMID: 34514091)
Mol Ther Oncolytics. 2017 Aug 24;7:1-11. (PMID: 28951885)
Viruses. 2012 May;4(5):688-707. (PMID: 22754644)
Mol Ther. 2007 Apr;15(4):651-9. (PMID: 17299401)
Gastroenterology. 2003 Oct;125(4):1203-18. (PMID: 14517802)
Virol J. 2004 Nov 22;1:10. (PMID: 15555076)
Front Microbiol. 2021 Feb 16;12:629971. (PMID: 33664719)
Mol Ther Oncolytics. 2021 Jun 04;22:399-409. (PMID: 34553028)
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22635-40. (PMID: 21149698)
Mol Ther Oncolytics. 2018 Apr 05;9:22-29. (PMID: 29988465)
J Virol. 2005 Oct;79(19):12125-31. (PMID: 16160140)
Semin Cell Dev Biol. 2016 Dec;60:89-96. (PMID: 27423915)
Blood. 2015 Jun 11;125(24):3778-88. (PMID: 25904246)
Rev Med Virol. 2007 Sep-Oct;17(5):313-26. (PMID: 17573668)
Rev Med Virol. 2019 Jan;29(1):e2013. (PMID: 30370570)
Mol Ther. 2012 Jun;20(6):1148-57. (PMID: 22273579)
Eur J Microbiol Immunol (Bp). 2014 Mar;4(1):26-33. (PMID: 24678403)
Virol J. 2011 Oct 26;8:481. (PMID: 22029482)
J Virol. 2005 Aug;79(16):10397-407. (PMID: 16051832)
J Cancer Res Ther. 2020 Jul-Sep;16(4):708-712. (PMID: 32930107)
Cancer Res. 2005 Apr 1;65(7):2832-9. (PMID: 15805284)
Nat Rev Cancer. 2009 Jan;9(1):64-71. (PMID: 19104515)
Cancer Res. 2007 Oct 15;67(20):10038-46. (PMID: 17942938)
Mol Ther Oncolytics. 2017 Dec 05;8:27-40. (PMID: 29367944)
Anticancer Res. 2011 Dec;31(12):4185-90. (PMID: 22199278)
J Clin Med. 2020 Jan 08;9(1):. (PMID: 31936317)
J Virol. 2018 Sep 26;92(20):. (PMID: 30045990)
Annu Rev Virol. 2014 Sep 1;1(1):119-141. (PMID: 25839047)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32217766)
J Gen Virol. 2008 Nov;89(Pt 11):2877-2881. (PMID: 18931086)
Nat Med. 1997 Jun;3(6):639-45. (PMID: 9176490)
Leukemia. 2009 Dec;23(12):2313-7. (PMID: 19865109)
Cancer Gene Ther. 2000 Jan;7(1):66-73. (PMID: 10678358)
J Virol. 2001 Nov;75(21):10300-8. (PMID: 11581398)
Cancer Gene Ther. 2020 Apr;27(3-4):125-135. (PMID: 31209267)
Biochem J. 2004 Jul 15;381(Pt 2):437-46. (PMID: 15025565)
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. (PMID: 26323545)
Nature. 1995 Jun 1;375(6530):411-5. (PMID: 7760935)
EMBO Mol Med. 2017 May;9(5):638-654. (PMID: 28289079)
Mol Ther Oncolytics. 2019 May 21;14:159-171. (PMID: 31236440)
Exp Ther Med. 2020 Nov;20(5):18. (PMID: 32934683)

R01 AI080607 United States AI NIAID NIH HHS; R21 CA249517 United States CA NCI NIH HHS

Keywords: DNA virus; adenovirus; herpesvirus; oncolytic virotherapy; oncolytic virus; poxvirus; tumor tropism

Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20231129

20240105

PMC10675630

10.3390/v15112262

38005938